SCI Pharmtech Inc
TWSE:4119
Intrinsic Value
The intrinsic value of one SCI Pharmtech Inc stock under the Base Case scenario is 70.42 TWD. Compared to the current market price of 83.1 TWD, SCI Pharmtech Inc is Overvalued by 15%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
SCI Pharmtech Inc
Fundamental Analysis

Revenue & Expenses Breakdown
SCI Pharmtech Inc
Balance Sheet Decomposition
SCI Pharmtech Inc
Current Assets | 2.1B |
Cash & Short-Term Investments | 543.5m |
Receivables | 869.5m |
Other Current Assets | 723.3m |
Non-Current Assets | 5.1B |
Long-Term Investments | 473.2m |
PP&E | 4.3B |
Intangibles | 39.8m |
Other Non-Current Assets | 302.6m |
Free Cash Flow Analysis
SCI Pharmtech Inc
TWD | |
Free Cash Flow | TWD |
Earnings Waterfall
SCI Pharmtech Inc
Revenue
|
1.4B
TWD
|
Cost of Revenue
|
-1B
TWD
|
Gross Profit
|
383.2m
TWD
|
Operating Expenses
|
-223.3m
TWD
|
Operating Income
|
159.9m
TWD
|
Other Expenses
|
324.3m
TWD
|
Net Income
|
484.2m
TWD
|
Profitability Score
Profitability Due Diligence
SCI Pharmtech Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
SCI Pharmtech Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
SCI Pharmtech Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
SCI Pharmtech Inc's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
SCI Pharmtech Inc
Dividends
Current shareholder yield for SCI Pharmtech Inc is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one SCI Pharmtech Inc stock under the Base Case scenario is 70.42 TWD.
Compared to the current market price of 83.1 TWD, SCI Pharmtech Inc is Overvalued by 15%.